ArticleInternational journal of clinical oncology2025

PMDA regulatory update on approval and revision of the precautions for use of anticancer drugs; approval of amivantamab plus lazertinib for non-small cell lung cancer, durvalumab for small cell lung cancer, tislelizumab for esophageal cancer, tisotumab vedotin for cervical cancer, ivosidenib for leukemia, and venetoclax for lymphoma in Japan.

Noriomi Matsumura et al.PubMed ↗Publisher ↗

No numbers read from the abstract.